Tobacco smoke carcinogens and lung cancer

Journal of the National Cancer Institute

Volumn 91, Issue 14, 1999, Pages 1194-1210

  Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; FREE RADICAL; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON;

ANIMAL CELL; ANIMAL TISSUE; CANCER PREVENTION; CIGARETTE SMOKING; HAMSTER; LUNG CARCINOGENESIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW; SMOKING; TOBACCO; TUMOR SUPPRESSOR GENE;

EID: 0033591845     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.14.1194     Document Type: Review

References (249)

1. Landis SH, Murray T, Belden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin;1999;49:8-31.
2. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Washington (DC): American Instiute for Cancer Research; 1997. p. 37
3. Blot WJ, Fraumeni JF Jr. Cancers of the lung and pleura. In: Schottenfeld, D, Fraumeni J Jr, editors. Cancer Epidemiology and Prevention. New York (NY): Oxford University Press; 1996. p. 637-65.
4. Surgeon General. Reducing the health consequences of smoking: 25 years of progress. Washington (DC): U.S. Gov Print Off; 1989.
5. Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect 1995; 103 Suppl 8:131-42.
6. Anonymous. Cigarette smoking among adults - United States 1995. Morb Mortal Wkly Rep 1995;46:1217-20.
7. Surgeon General. Smoking and health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington (DC): U.S. Gov Print Off; 1964.
8. American Cancer Society. Cancer Facts and Figures - 1996. Atlanta (GA): American Cancer Society; 1996. p. 24.
9. National Cancer Institute. Changes in cigarette-related disease risks and their implication for prevention and control. In: Smoking and Tobacco Control Monograph 8. Bethesda (MD): National Institutes of Health Publ No. 97-4213; 1996. p. 13-112.
10. Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. Br Med Bull 1996;52:3-11.
11. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
12. Environmental Health Hazard Assessment, California Environmental Protection Agency. Health effects of exposure to environmental tobacco smoke. Sacramento (CA): California Environmental Protection Agency; 1997.
13. Dockery DW, Trichopoulos D. Risk of lung cancer from environmental exposures to tobacco smoke. Cancer Causes Control 1997;8:333-45.
14. Environmental Protection Agency (EPA). Respiratory health effects of passive smoking: lung cancer and other disorders. Report No. EPA/600/ 6-90/006F. Office of Health and Environmental Assessment, Office of Research and Development. Washington (DC): EPA; 1992.
15. United States Department of Health and Human Services. The health consequences of involuntary smoking: a report of the Surgeon General. Washington (DC): Department of Health and Human Services; 1986.
16. Boffetta P, Agudo A, Ahrens W, Benhamou E, Benhamou S, Darby SC, et al. Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. J Natl Cancer Inst 1998;90: 1440-50.
17. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995;92:5258-65.
18. Surgeon General. The health consequences of smoking: nicotine addiction. Washington (DC): U.S. Gov Print; 1988.
19. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64.
20. Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Cooper CS. Grover PL, editors. Handbook of experimental pharmacology. Vol 94/I. Heidelberg (Germany): Springer-Verlag; 1990. p. 63-102.
21. Hecht SS. Cigarette smoking and cancer. In: Rom WN, editor. Environmental and occupational medicine. New York (NY): Lippincott-Raven; 1998. p. 1479-99.
22. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:559-603.
23. Conney AH. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res 1982;42:4875-917.
24. Miller JA. Research in chemical carcinogenesis with Elizabeth Miller - a trail of discovery with our associates. Drug Metab Dispos 1994;26:1-36.
25. Miller EC, Miller JA. Searches for the ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 1981;47: 2327-45.
26. Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerback D, Bartsch H. DNA adducts: identification and biological significance. IARC Sci Publ No. 125. Lyon (France): IARC; 1994.
27. Geacintov NE, Cosman M, Hingerty BE, Amin S, Broyde S, Patel DJ. NMR solution structures of stereoisomeric covalent polycyclic aromatic carcinogen-DNA adducts: principles, patterns, and diversity. Chem Res Toxicol 1997;10:111-46.
28. Singer B, Essigmann JM. Site-specific mutagenesis: retrospective and prospective. Carcinogenesis 1991;12:949-55.
29. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-73.
30. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378: F21-59.
31. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995;55:1444-7.
32. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 1996;56:2224-8.
33. Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993;72:432-8.
34. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
35. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;85:4023-37.
36. Olshan AF, Weissler MC, Pei H, Conway K. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 1997;6:499-504.
37. Smith TJ, Livingston SD, Doolittle OJ. An international literature survey of "IARC group I carcinogens" reported in mainstream cigarette smoke. Food Chem Toxicol 1997;35:1107-30.
38. International Agency for Research on Cancer (IARC). Tobacco smoking. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 38. Lyon (France): IARC; 1986. p. 37-375.
39. Snook ME, Severson RF, Arrendale RF, Higman HC, Chortyk OT. Multialkylated polynuclear aromatic hydrocarbons of tobacco smoke: separation and identification. Beitr Tabakforsch 1978;9:222-47.
40. Snook ME, Severson RF, Arrendale RF, Higman HC, Chortyk OT. The identification of high molecular weight polynuclear aromatic hydrocarbons in a biologically active fraction of cigarette smoke condensate. Beitr Tabakforsch 1977;9:79-101.
41. International Agency for Research on Cancer (IARC). Certain polycyclic aromatic hydrocarbons and heterocyclic compounds. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Vol 3. Lyon (France): IARC; 1972. p. 45-268.
42. International Agency for Research on Cancer (IARC). Polynuclear aromatic compounds, part 1, chemical, environmental, and experimental data. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 32. Lyon (France): IARC; 1983. p. 33-451.
43. Deutsch-Wenzel RP, Brune H, Grimmer G, Dettbarn G, Misfeld J. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst 1983;71:539-44.
44. Sellakumar A, Shubik P. Carcinogenicity of different polycyclic hydrocarbons in the respiratory tract of hamsters. J Natl Cancer Inst 1974;53: 1713-9.
45. Nesnow S, Ross JA, Stoner GD, Mass MJ. Mechanistic linkage between DNA adducts, mutations in oncogenes and tumorigenesis of carcinogenic environmental polycyclic aromatic hydrocarbons in strain A/J mice. Toxicology 1995;105:403-13.
46. Deutsch-Wenzel RP, Brune H, Grimmer G. Experimental studies on the carcinogenicity of five nitrogen containing polycyclic aromatic compounds directly injected into rat lungs. Cancer Lett 1983;20: 97-101.
47. Sellakumar A, Starback F, Rowland J, Shubik P. Tumor induction by 7H-dibenzo[c,g]carbazole in the respiratory tract of Syrian hamsters. J Toxicol Environ Health 1977:3:935-9.
48. International Agency for Research on Cancer (IARC). Some N-nitroso Compounds. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 17. Lyon (France): IARC; 1983. p. 83-124.
49. Reznik-Shuller HM. Cancer induced in the respiratory tract of rodents by N-nitroso compounds. In: Reznik-Shuller HM, editor. Comparative respiratory tract carcinogens. Vol II. Boca Raton (FL): CRC Press, Inc.; 1983. p. 109-59.
50. International Agency for Research on Cancer (IARC). Tobacco habits other than smoking: betel quid and areca nut chewing, and some related nitrosamines. In: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Vol 37. Lyon (France): IARC; 1983. p. 205-8.
51. International Agency for Research on Cancer (IARC). Occupational exposures to mists and vapours from strong inorganic acids; and some other industrial chemicals. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 54. Lyon (France): IARC; 1992. p. 237-85.
52. International Agency for Research on Cancer (IARC). Some antithyroid and related substances, nitrofurans and industrial chemicals. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Vol 7. Lyon (France): IARC; 1974. p. 111-40.
53. International Agency for Research on Cancer (IARC). Chromium, nickel and welding. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 49. Lyon (France): IARC; 1990. p, 49-245.
54. International Agency for Research on Cancer (IARC). Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. In; IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 58. Lyon (France): IARC; 1993. p. 119-237.
55. International Agency for Research on Cancer (IARC). Man-made mineral fibers and radon. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 43. Lyon (France): IARC; 1988. p. 173-259.
56. Little JB, McGandy RB, Kennedy AR. Interactions between polonium-210 alpha-radiation, benzo(a)pyrene, and 0.9% NaCl solution instillations in the induction of experimental lung cancer. Cancer Res 1978;38: 1929-35.
57. Little JB, O'Toole WF. Respiratory tract tumors in hamsters induced by benzo(a)pyrene and 210Po alpha-radiation. Cancer Res 1974;34:3026-39.
58. Yuile CL, Berke HL, Hull T. Lung cancer following polonium-210 inhalation in rats. Rad Res 1967;31:760-3.
59. International Agency for Research on Cancer (IARC). Some metals and metallic compounds. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 23. Lyon (France): IARC; 1980. p. 39-141.
60. International Agency for Research on Cancer (IARC). Some aromatic amines, hydrazine and related substances, N-nitroso compounds and miscellaneous alkylating agents. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Vol 4. Lyon (France): IARC; 1973. p. 127-36.
61. Guerin MR, Jenkins RA, Tomkins BA. the chemistry of environmental tobacco smoke: composition and management. Chelsea (MA): Lewis Publishers; 1992.
62. Thyssen J, Althoff J, Kimmerle G, Mohr U. Inhalation studies with benzo[a]pyrene in Syrian golden hamsters. J Natl Cancer Inst 1981;66:575-7.
63. Wolterbeek AP, Schoevers EJ, Rutten AA, Feron VJ. A critical appraisal of intratracheal instillation of benzo[a]pyrene to Syrian golden hamsters as a model in respiratory tract carcinogenesis. Cancer Lett 1995;89: 107-16.
64. Culp SJ, Gaylor DW, Sheldon WG, Goldstein LS, Beland FA. A comparison of the tumors induced by coal tar and benzo[a]pyrene in a 2-year bioassay. Carcinogenesis 1998;19:117-24.
65. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988; 9:875-84.
66. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J Toxicol Environ Health 1994;41:1-52.
67. Spiegelhalder B, Bartsch H. Tobacco-specific nitrosamines. Eur J Cancer Prev 1996;5 Suppl 1:33-8.
68. Harley NB, Cohen BS, Tso TC. Polonium-210: a questionable risk factor in smoking related carcinogenesis. Banbury Report 3: a safe cigarette? Cold Spring Harbor (NY): Cold Spring Harbor Laboratory; 1980. p. 93-104.
69. Blot WJ, McLaughlin JK. Passive smoking and lung cancer risk: what is the story now? [editorial]. J Natl Cancer Inst 1998;90:1416-7.
70. Hecht SS. Carcinogenic effects of cigarette smoke on the respiratory tract. In: Roth RA, editor. Comprehensive toxicology: toxicology of the respiratory system. Vol 8. Oxford (U.K.): Elsevier Science; 1997. p. 437-51.
71. 1 mice. J Natl Cancer Inst 1986;77:203-12.
72. Finch GL, Nikula KJ, Belinsky SA, Barr EB, Stoner GD, Lechner JF. Failure of cigarette smoke to induce or promote lung cancer in the A/J mouse. Cancer Lett 1996;99:161-7.
73. Witschi H, Espiritu I, Peake JL, Wu K, Maronpot RR, Pinkerton KE. The carcinogenicity of environmental tobacco smoke. Carcinogenesis 1997; 18:575-86.
74. Witschi H, Espiritu I, Maronpot RR, Pinkerton KE, Jones AD. The carcinogenic potential of the gas phase of environmental tobacco smoke. Carcinogenesis 1997;18:2035-42.
75. Guengerich FP. Cytochrome P450 enzymes. In: Guengerich FP, editor. Comprehensive toxicology: biotransformation. Vol 3. Oxford (U.K.): Elsevier Science; 1997. p. 37-68.
76. Armstrong RN. Glutathione-S-transferases. In: Guengerich FP, editor. Comprehensive toxicology: biotransformation. Vol 3. Oxford (U.K.): Elsevier Science; 1997. p. 307-27.
77. Burchell B, McGurk K, Brierley CH, Clarke DJ. UDP-glucuronosyltransferases. In: Guengerich FP, editor. Comprehensive toxicology: biotransformation. Vol 3. Oxford (U.K.): Elsevier Science; 1997. p. 401-36.
78. Duffel MW. Sulfotransferases. In: Guengerich FP, editor. Comprehensive toxicology: biotransformation. Vol 3. Oxford (U.K.): Elsevier Science; 1997. p. 365-84.
79. Gelboin HV. Benzo[a]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxides and related enzymes. Physiol Rev 1980:60:1107-66.
80. Cooper CS, Grover PL, Sims P. The metabolism and activation of benzo[a]pyrene. In: Bridges JW, Chasseaud LF, editors. Progress in drug metabolism. New York (NY): John Wiley & Sons; 1983. p. 295-396.
81. Pelkonen O, Nebert DW. Metabolism of polycyclic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 1982;34:189-222.
82. Conney AH, Chang RL, Jerina DM, Wei SJ. Studies on the metabolism of benzo[o]pyrene and dose-dependent differences in the mutagenic profile of its ultimate carcinogenic metabolite. Drug Metab Rev 1994;26:125-63.
83. Hecht SS. Carcinogenesis due to tobacco: molecular mechanisms. In: Bertino JR, editor. Encyclopedia of cancer. San Diego (CA): Academic Press; 1996. p. 220-32.
84. Baird WM, Ralston SL. Carcinogenic polycyclic aromatic hydrocarbons. In: Bowden GT, Fischer SM, editors. Comprehensive toxicology: chemical carcinogens and anticarcinogens. Vol 12. 1997. p. 171-200.
85. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, et al. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 1992;98:87-94.
86. Jernstrom B, Funk M, Frank H, Mannervik B, Seidel A. Glutathione S-transferase A1-1-catalysed conjugation of bay and fjord region diol epoxides of polycyclic hydrocarbons with glutathione. Carcinogenesis 1996; 17:1491-8.
87. Sundberg K, Widersten M, Seidel A, Mannervik B, Jernstrom B. Glutathione conjugation of bay-and fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase M1-1 and P1-1. Chem Res Toxicol 1997;10:1221-7.
88. Yun CH, Shimada T, Guengerich FP. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo[a]pyrene. Cancer Res 1992;52:1868-74.
89. Bauer E, Guo Z, Ueng YF, Bell LC, Zeldin D, Guengerich FP. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 1995;8:136-42.
90. Shou M, Korzekwa KR, Crespi CL, Gonzalez FJ, Gelboin HV. The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol Carcinog 1994;10:159-68.
91. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979-84.
92. Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter TR. Metabolism of benzo[a]pyrene and benzo[u]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1998;19:1847-53.
93. Penning TM, Burczynski ME, Hung CF, McCoull KD, Palackal NT, Tsuruda LS. Dihydrodiol dehydrogenses and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active O-quinones. Chem Res Toxicol 1999;12:1-18.
94. Friedberg T, Becker R, Oesch F, Glatt H. Studies on the importance of microsomal epoxide hydrolase in the detoxification of arene oxides using the heterologous expression of the enzyme in mammalian cells. Carcinogenesis 1994;15:171-5.
95. Smith TJ, Guo Z, Gonzalez FJ, Guengerich FP, Stoner GD, Yang CS. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res 1992;52:1757-63.
96. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992;13:1789-94.
97. Tiano HF, Hosokawa M, Chulada PC, Smith PB, Wang RL, Gonzalez FJ, et al. Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis 1993;14:1421-7.
98. Smith TJ, Stoner GD, Yang CS. Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res 1995;55: 5566-73.
99. Patten CJ, Smith TJ, Murphy SE, Wang MH, Lee J, Tynes RE, et al. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridy)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch Biochem Biophys 1996;333:127-8.
100. Staretz ME, Murphy SE, Patten CJ, Nunes MG, Koehl W, Amin S, et al. Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N′-nitrosonornicotine in human hepatic microsomes. Drug Metab Dispos 1997;25:154-62.
101. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996;18:188-204.
102. Carmella SG, Akerkar S, Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. Cancer Res 1993;53:721-4.
103. Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993;329:1543-6.
104. Carmella SG, Akerkar SA, Richie JP Jr, Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiol Biomarkers Prev 1995;4:635-42.
105. Carmella SG, Borukhova A, Akerkar SA, Hecht SS. Analysis of human urine for pyridine-N-oxide metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific lung carcinogen. Cancer Epidemiol Biomarkers Prev 1997;6:113-20.
106. Meger M, Meger-Kossien I, Dietrich M, Tricker AR, Scherer G, Adlkofer F. Metabolites of 4-(N-methylnitrosamino)-1-(3-pyridyl)-1-butanone in the urine of smokers [published erratum appears in Eur J Cancer Prev 1997;6:99]. Eur J Cancer Prev 1996;5 Suppl 1:121-4.
107. Parsons WD, Carmella SG, Akerkar S, Bonilla LE, Hecht SS. A metabolite of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the urine of hospital workers exposed to environmental tobacco smoke. Cancer Epidemiol Biomarkers Prev 1998;7: 257-60.
108. Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht SS. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev 1997;6:783-90.
109. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1998;280:135-9.
110. Perez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA 1998;280:152-56.
111. Tokiwa H, Sera N, Horikawa K, Nakanishi Y, Shigematu N. The presence of mutagens/carcinogens in the excised lung and analysis of lung cancer induction. Carcinogenesis 1993;14:1933-8.
112. Seto H, Ohkubo T, Kanoh T, Koike M, Nakamura K, Kawahara Y. Determination of polycyclic aromatic hydrocarbons in the lung. Arch Environ Contam Toxicol 1993;24:498-503.
113. Jongeneelen FJ. Methods for routine biological monitoring of carcinogenic PAH-mixtures. Sci Total Environ 1997;199:141-9.
114. Strickland P, Kang D, Sithisarankul P. Polycyclic aromatic hydrocarbon metabolites in urine as biomarkers of exposure and effect. Environ Health Perspect 1996;104 Suppl 5:927-32.
115. Sithisarankul P, Vineis P, Kang D, Rothman N, Caporaso N, Strickland P. The association of 1-hydroxypyrene-glucuronide in human urine with cigarette smoking and broiled or roasted meat consumption. Biomarkers 1997;2:217-21.
116. Ariese F, Verkaik M, Hoornweg GP, van de Nesse RJ, Jukema-Leenstra SR, Hofstraat JW, et al. Trace analysis of 3-hydroxy benzo[a]pyrene in urine for the biomonitoring of human exposure to polycyclic aromatic hydrocarbons. J Anal Toxicol 1994;18:195-204.
117. Grimmer G, Jacob J, Dettbarn G, Naujack KW. Determination of urinary metabolites of polycyclic aromatic hydrocarbons (PAH) for the risk assessment of PAH-exposed workers. Int Arch Occup Environ Health 1997; 69:231-9.
118. Mumford JL, Li X, Hu F, Lu XB, Chuang JC. Human exposure and dosimetry of polycyclic aromatic hydrocarbons in urine from Xuan Wei, China, with high lung cancer mortality associated with exposure to unvented coal smoke. Carcinogenesis 1995;16:3031-6.
119. Becher G, Bjorseth A. Determination of exposure to polycyclic aromatic hydrocarbons by analysis of human urine. Cancer Lett 1983;17:301-11.
120. Haugen A, Becher G, Benestad C, Vahakangas K, Trivers GE, Newman MJ, et al. Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a)pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res 1986;46:4178-83.
121. Weston A, Bowman ED, Carr P, Rothman N, Strickland PT. Detection of metabolites of polycyclic aromatic hydrocarbons in human urine. Carcinogenesis 1993;14:1053-5.
122. Bowman ED, Rothman N, Hackl C, Santella RM, Weston A. Interindividual variation in the levels of certain urinary polycyclic aromatic hydrocarbon metabolites following medicinal exposure to coal tar ointment. Biomarkers 1997;2:321-7.
123. Bartsch H. DNA adducts in human Carcinogenesis: etiological relevance and structure-activity relationship. Mutat Res 1996;340:67-79.
124. Petruzzelli S, Camus AM, Carrozzi L, Ghelarducci L, Rindi M, Menconi G, et al. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res 1988;48:4695-700.
125. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990;82:1333-9.
126. Rojas M, Camus AM, Alexandrov K, Husgafvel-Pursiainen K, Anttila S, Vainio H, et al. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis 1992;13:929-33.
127. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, et al. An improved fluorometric assay for dosimetry of benzo-[a]pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 1992;52:6248-53.
128. Rojas M, Alexandrov K, Cascarbi I, Brockmoller J, Likhachev A, Pozharisski K, et al. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics 1997;8:109-18.
129. Weston A, Bowman ED. Fluorescence detection of benzo[a]pyrene-DNA adducts in human lung. Carcinogenesis 1991;12:1445-9.
130. Corley J, Hurtubise RJ, Bowman ED, Weston A. Solid matrix, room temperature phosphorescence identification and quantitation of the tetrahydrotetrols derived from the acid hydrolysis of benzo[a]pyrene-DNA adducts from human lung. Carcinogenesis 1995;16:423-6.
131. Poirier MC, Weston A. Human DNA adduct measurements: state of the art. Environ Health Perspect 1996;104 Suppl 5:883-93.
132. Phillips DH. DNA adducts in human tissues: biomarkers of exposure to carcinogens in tobacco smoke. Environ Health Perspect 1996;104 Suppl 3:453-8.
133. Santella RM. DNA adducts in humans as biomarkers of exposure to environmental and occupational carcinogens. Environ Carcinog Ecotoxicol Rev 1991;C9:57-81.
134. Tang D, Santella RM, Blackwood AM, Young TL, Mayer J, Jaretzki A, et al. A molecular epidemiological case-control of lung cancer. Cancer Epidemiol Biomarkers Prev 1995;4:341-6.
135. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994;54:5801-3.
136. Godschalk RWL, Maas LM, Van Zandwijk N, van't Veer LJ, Breedijk A, Borm PJ, et al. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers. Carcinogenesis 1998;19:819-25.
137. Kriek E, Rojas M, Alexandrov K, Bartsch H. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat Res 1998;400:215-31.
138. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994;54:5801-3.
139. Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Baera R, Haugen A. p53 mutations in lung tumors: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996;17:2201-5.
140. Zang EA, Wynder EL. Differences in lung cancer risks between men and women: Examination of the evidence. J Natl Cancer Inst 1996;88:183-92.
141. Brunmark P, Harriman S, Skipper PL, Wishnok JS, Amin S, Tannenbaum SR. Identification of subdomain IB in human serum albumin as a major binding site for polycyclic aromatic hydrocarbon epoxides. Chem Res Toxicol 1997;10:880-6.
142. Day BW, Naylor S, Gan LS, Sahali Y, Nguyen TT, Skipper PL, et al. Molecular dosimetry of polycyclic aromatic hydrocarbon epoxides and diol epoxides via hemoglobin adducts. Cancer Res 1990;50:4611-8.
143. Day BW, Naylor S, Gan LS, Sahali Y, Nguyen TT, Skipper PL, et al. Gas chromatographic-mass spectrometric analysis of diols and tetrols from reactions of polycyclic aromatic hydrocarbon epoxides with hemoglobin. J Chromatogr 1991;562:563-71.
144. Day BW, Skipper PL, Zaia J, Singh K, Tannenbaum SR. Enantiospecificity of covalent adduct formation by benzo[a]pyrene anti-diol epoxide with human serum albumin. Chem Res Toxicol 1994;7:829-35.
145. Myers SR, Spinnato JA, Pinorini MT. Chromatographic characterization of hemoglobin benzo[a]pyrene-7,8-diol-9,10-epoxide adducts. Fundam Appl Toxicol 1996;29:94-101.
146. Pastorelli R, Restano J, Guanci M, Maramonte M, Magagnotti C, Allevi R, et al. Hemoglobin adducts of benzo[a]pyrene diolepoxide in newspaper vendors: association with traffic exhaust. Carcinogenesis 1996;17: 2389-94.
147. 3I postlabeling of released tetraols. Chem Res Toxicol 1996;9:508-16.
148. Melikian AA, Sun P, Pierpont C, Coleman S, Hecht SS. Gas chromatographic-mass spectrometric determination of benzo[a]pyrene and chrysene diol epoxide globin adducts in humans. Cancer Epidemiol Biomarkers Prev 1997;6:833-9.
149. 32P-postlabeling assay. Carcinogenesis 1993;14:545-50.
150. 7-methyldeoxyguanosine. Cancer Res 1990;50:6580-4.
151. 32P-postlabeling analysis of 7-methylguanine in human bronchial and lymphocyte DNA. Carcinogenesis 1993;14:151-4.
152. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Cancer Inst 1995;87:902-7.
153. Blomeke B, Greenblatt MJ, Doan VD, Bowman ED, Murphy SE, Chen CC, et al. Distribution of 7-alkyl-2′-deoxyguanosine adduct levels in human lung. Carcinogenesis 1996;17:741-8.
154. 7-methyldeoxyguanosine adducts in human pulmonary alveolar cells. Am J Respir Cell Mol Biol 1996;15:216-23.
155. Wilson VL, Weston A, Manchester DK, Trivers GE, Roberts DW, Kadlubar FF, et al. Alkyl and aryl carcinogen adducts detected in human peripheral lung. Carcinogenesis 1989;10:2149-53.
156. Foiles PG, Akerkar SA, Carmella SG, Kagan M, Stoner GD, Resau JH, et al. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem Res Toxicol 1991;4:364-8.
157. Carmella SG, Kagan SS, Kagan M, Foiles PG, Palladino G, Quart AM, et al. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers, and nonsmokers. Cancer Res 1990; 50:5438-45.
158. Falter B, Kutzer C, Richter E. Biomonitoring of hemoglobin adducts: aromatic amines and tobacco-specific nitrosamines. Clin Investig 1994; 72:364-71.
159. Kutzer C, Branner B, Zwickenpflug W, Richter E. Simultaneous solid-phase extraction and gas chromatographic-mass spectrometric determination of hemoglobin adducts from tobacco-specific nitrosamines and aromatic amines. J Chromatogr Sci 1997;35:1-7.
160. Atawodi SE, Lea S, Nyberg F, Mukeria A, Constantinescu V, Ahrens W, Brueske-Hohlfield I, et al. 4-Hydroxy-1-(3-pyridyl)-1-butanone-hemoglobin adducts as biomarkers of exposure to tobacco smoke: validation of a method to be used in multicenter studies. Cancer Epidemiol Biomarkers Prev 1998;7:817-21.
161. Kopplin A, Eberle-Adamkiewicz G, Glusenkamp KH, Nehls P, Kirstein U. Urinary excretion of 3-methyladenine and 3-ethyladenine after controlled exposure to tobacco smoke. Carcinogenesis 1995;16:2637-41.
162. Prevost V, Shuker DE. Cigarette smoking and urinary 3-alkyladenine excretion in man. Chem Res Toxicol 1996;9:439-44.
163. Sancar A. DNA excision repair. Ann Rev Biochem 1996;65:43-81.
164. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mole Biol 1995;51:167-223.
165. Singer B, Hang B. What structural features determine repair enzyme specificity and mechanism in chemically modified DNA? Chem Res Toxicol 1997;10:713-32.
166. 6-methylguanine-DNA methyltransferase and uracil DNA glycosylase in human broncho-alveolar lavage cells and peripheral blood mononuclear cells from tobacco smokers and non-smokers. Carcinogenesis 1991;12:1389-94.
167. 6-methylguanine-DNA methyltransferase and uracil-DNA glyosylase in human placentae from smokers and non-smokers. Carcinogenesis 1992; 13:1769-73.
168. 6-alkylguanine-DNA alkyltransferase activity in human lung tissue. Carcinogenesis 1994;15:1535-9.
169. 6-methylguanine-DNA methyltransferase expression in human lung carcinomas. Carcinogenesis 1998;19:1247-50.
170. 6-methylguanine in rat pulmonary cells. Carcinogenesis 1988;9:2053-8.
171. 6-alkylguanine-DNA alkyltransferase. Chem Res Toxicol 1996;9:949-53.
172. 6-alkylguanine-DNA alkytransferase. Chem Res Toxicol 1997;10:562-7.
173. 6-methylguanine. Cancer Res 1993;53:2780-5.
174. Tang MS, Pierce JR, Doisy RP, Nazimiec ME, MacLeod MC. Differences and similarities in the repair of two benzo[a]pyrene diol isomers induced DNA adducts by uvrA, uvrB, and uvrC gene products. Biochemistry 1992;31:8429-36.
175. Chen RH, Maher VM, Brouwer J, van de Putte P, McCormick JJ. Preferential repair and strand-specific repair of benzo[a]pyrene diol epoxide adducts in the HPRT gene of diploid human fibroblasts. Proc Natl Acad Sei USA 1992;89:5413-7.
176. Hess MT, Gunz D, Luneva N, Geacintov NE, Naegeli H. Base pair con-formation-dependent excision of benzo[a]pyrene diol epoxide-guanine adducts by human nucleotide excision repair enzymes. Mol Cell Biol 1997;17:7069-76.
177. Wei Q, Spitz MR. The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev 1997;16:295-307.
178. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 1997;105 Suppl 4:875-82.
179. Flicker TM, Green SA. Detection and separation of gas-phase carbon-centered radicals from cigarette smoke and diesel exhaust. Anal Chem 1998;70:2208-12.
180. Pryor WA, Hales BJ, Premovic PI, Church DF. The radicals in cigarette tar: their nature and suggested physiological implications. Science 1983; 220:425-7.
181. Pryor WA, Stone K, Zang LY, Bermudez E. Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem Res Toxicol 1998;11:441-8.
182. Nakayama T, Kodama M, Nagata C. Generation of hydrogen peroxide and Superoxide anion radical from cigarette smoke. Gann 1984;75:95-8.
183. Nakayama T, Kaneko M, Kodama M, Nagata C. Cigarette smoke induces DNA single-strand breaks in human cells. Nature 1985;314:462-4.
184. Nakayama T, Kaneko M, Kodama M. Volatile gas components contribute to cigarette smoke induced DNA single strand breaks in cultured human cells. Agric Biol Chem 1986;50:3219-20.
185. Fielding S, Short C, Davies K, Wald N, Bridges BA, Waters R. Studies on the ability of smoke from different types of cigarettes to induce DNA single-strand breaks in cultured human cells. Mutat Res 1989;214:147-51.
186. Leanderson P, Tagesson C. Cigarette smoke-induced DNA-damage: role of hydroquinone and catechol in the formation of the oxidative DNA-adduct, 8-hydroxydeoxyguanosine. Chem Biol Interact 1990;75:71-81.
187. Leanderson P, Tagesson C. Cigarette smoke-induced DNA damage in cultured human lung cells: role of hydroxyl radicals and endonuclease activation. Chem Biol Interact 1992;81:197-208.
188. Yoshie Y, Ohshima H. Synergistic induction of DNA strand breakage by cigarette tar and nitric oxide. Carcinogenesis 1997;18:1359-63.
189. Muller T, Haussmann HJ, Schepers G. Evidence of peroxynitrite as an oxidative stress-inducing compound of aqueous cigarette smoke fractions. Carcinogenesis 1997;18:295-301.
190. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Biochem J 1991;277:133-8.
191. Reznick AZ, Cross CE, Hu ML, Suzuki YJ, Khwaja S, Safadi A, et al. Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem J 1992;286:607-11.
192. Schechtman G, Byrd JC, Hoffmann R. Ascorbic acid requirements for smokers: analysis of a population survey. Am J Clin Nutr 1991;53: 1466-70.
193. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
194. Asami S, Manabe H, Miyake J, Tsurudome Y, Hirano T, Yamaguchi R, et al. Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis 1997;18:1763-6.
195. Asami S, Hirano T, Yamaguchi Y, Tomioka Y, Itoh H, Kasai H. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res 1996;56: 2546-9.
196. Fraga CG, Motchnik PA, Wyrobek AJ, Rempel DM, Ames BN. Smoking and low antioxidant levels increase oxidative damage to sperm DNA. Mutat Res 1996;351:199-203.
197. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis 1992;13:2241-7.
198. Prieme H, Loft S, Klarlund M, Gronbaek K, Tonnesen P, Poulsen HE. Effect of smoking cessation on oxidative DNA modification estimated by 8-oxo-7,8-dihydro-2′-deoxyguanosine excretion. Carcinogenesis 1998; 19:347-51.
199. Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, et al. p53 mutations in lung cancer from nonsmoking atomic-bomb survivors. Lancet 1993;342:1520-1.
200. Chen JX, Zheng Y, West M, Tang M. Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res 1998;58: 2070-5.
201. Denissenko MF, Pao A, Tang M. Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
202. Denissenko MF, Chen JX, Tang MS, Pfeifer GP. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc Natl Acad Sci U S A 1997;94:3893-8.
203. Delclos KB, Kadlubar FF. Carcinogenic aromatic amines and amides. In: Guengerich FP, editor. Comprehensive toxicology: chemical carcinogens and anticarcinogens. Vol 12. Oxford (U.K.): Elsevier Science; 1997. p. 141-70.
204. 2-dG adduct of (+)-anti-B[a]PDE shows a dramatically different mutagenic specificity (predominantly, G→A) in a 5′-CGT-3′ sequence context. Biochemistry 1997;36:10256-61.
205. Moriya M, Zhang W, Johnson F, Grollman AP. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proc Natl Acad Sci U S A 1994;91:11899-903.
206. Moriya M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G.C→T.A transversions in simian kidney cells. Proc Natl Acad Sci USA 1993;90: 1122-6.
207. Ronai ZA, Gradia S, Peterson LA, Hecht SS. G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis 1993;14:2419-22.
208. Burcham PC, Marnett LJ. Site-specific mutagenesis by a propanodeoxyguanosine adduct carried on an M13 genome. J Biol Chem 1994;269: 28844-50.
209. Nesnow S, Ross JA, Mass MJ, Stoner GD. Mechanistic relationships between DNA adducts, oncogene mutations, and lung tumorigenesis in strain A mice. Exp Lung Res 1998;24:395-405.
210. Belinsky SA, Swafford DS, Finch GL, Mitchell CE, Kelly G, Hahn FF, et al. Alterations in the K-ras and p53 genes in rat lung tumors. Env Health Perspect 1997;105 Suppl 4:901-6.
211. Merlo A, Herman JG, Mao L, Lee DL, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1:686-92.
212. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-8.
213. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-6.
214. Sabourin CL, Wang QS, Ralston SL, Evans J, Coate J, Herzog CR, et al. Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors. Exp Lung Res 1998;24: 499-521.
215. Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996;56:3655-8.
216. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiana DC, Kelsey KT. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804-7.
217. Rothman N, Stewart WF, Schulte PA. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epidemiol Biomarkers Prev 1995;4:301-11.
218. Perera FP. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 1996;88:496-509.
219. Rannug A, Alexandrie AK, Persson J, Ingelman-Sundberg M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 1995;37:25-36.
220. Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The molecular epidemiology of lung cancer. Crit Rev Toxicol 1997;27:319-65.
221. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19:1329-32.
222. Zhang ZY, Fasco MJ, Huang L, Guengerich FP, Kaminsky LS. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Va1462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996;56:3926-33.
223. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
224. Wu MT, Huang SL, Ho CK, Yeh YF, Christiani DC. Cytochrome P450 1A1 MspI. polymorphism and urinary 1-hydroxypyrene concentrations in coke-oven workers. Cancer Epidemiol Biomarkers Prev 1998;7:823-9.
225. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984;312:169-70.
226. Caporaso NE, DeBaun MR, Rothman N. Lung cancer and CYP 2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 1998;5:5129-34.
227. Shaw GL, Falk RT, Frame JN, Weiffenbach B, Nesbitt JC, Pass HI, et al. Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:215-9.
228. Crespi CL, Penman BW, Gelboin HV, Gonzalez F. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991;12:1197-201.
229. Penman BW, Reece J, Smith T, Yang CS, Gelboin HV, Gonzalez FJ, et al. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics 1993;3:28-9.
230. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998;58:4858-63.
231. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:589-94.
232. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
233. Tang DL, Rundle A, Warburton D, Santella RM, Tsai WY, Chiamprasert S, et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 1998;19:1949-53.
234. el-Zein R, Zwischenberger JB, Wood TG, Abdel-Rahman SZ, Brekelbaum C, Au WW. Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 1997;381:189-200.
235. Hsu TC, Spitz MR, Schantz SP. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1991;1:83-9.
236. Klein-Szanto AJ, Iizasa T, Momiki S, Garcia-Palazzo I, Caamano J, Metcalf R, et al. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells. Proc Natl Acad Sci U S A 1992;89:6693-7.
237. Hoffmann D, Rivenson A, Murphy SE, Chung FL, Amin S, Hecht SS. Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived N-nitrosamines. J Smoking-Related Disorders 1993;4: 165-89.
238. Wynder EL, Hoffmann D. Re: Cigarette smoking and the histopathology of lung cancer. J Natl Cancer Inst 1998;90:1486-8.
239. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-9.
240. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
241. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
242. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 1994;271:595-607.
243. Hughes JR. The future of smoking cessation therapy in the United States. Addiction 1996;91:1797-802.
244. Emmons KM, Kawachi I, Barclay G. Tobacco control - a brief review of its history and progress for the future. Hematol Oncol Clin North Am 1997;11:177-95.
245. Hecht SS. Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Environ Health Perspect 1997;105 Suppl 4:955-63.
246. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 1996; 26:1-28.
247. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997;57:5489-92.
248. Hecht SS, Kenney PM, Wang M, Trushin N, Agarwal S, Rao AV, et al. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol, and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1 -butanone-induced lung tumorigenesis in A/J mice. Cancer Lett. In press 1998.
249. You M, Bergman G. Preclinical and clinical models of lung cancer chemoprevention. Hematol Oncol Clin North Am 1998;12:1037-53.